Literature DB >> 3894422

Molecular analysis of the bare lymphocyte syndrome.

K E Sullivan, J D Stobo, B M Peterlin.   

Abstract

The bare lymphocyte syndrome is a disorder in which class I histocompatibility antigens fail to be expressed normally on the surface of lymphocytes. Utilizing complementary DNA probes for both beta 2-microglobulin and class I genes, the molecular basis for this syndrome was investigated in a family with two siblings exhibiting the bare lymphocyte syndrome. Southern blot analysis demonstrated no gross internal defect in either class I or beta 2-microglobulin genes. Northern blot analysis of class I and beta 2-microglobulin messenger RNAs also revealed no qualitative difference between affected and unaffected family members. In contrast, quantitation of both class I and beta 2-microglobulin transcripts demonstrated each to be decreased in patients when compared to controls. Moreover, the decrease in both transcripts was coordinate. These results suggest that the bare lymphocyte syndrome may represent a pretranslational regulatory defect of both class I and beta 2-microglobulin gene expression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894422      PMCID: PMC423710          DOI: 10.1172/JCI111980

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Failure of lymphocyte-membrane HLA-A and -B expression in two siblings with combined immunodeficiency.

Authors:  R K Schuurman; J J van Rood; J M Vossen; P T Schellekens; T M Feltkamp-Vroom; E Doyer; F Gmelig-Meyling; H K Visser
Journal:  Clin Immunol Immunopathol       Date:  1979-12

Review 2.  The cell surface antigens of mouse embryonal carcinoma cells.

Authors:  G Gachelin
Journal:  Biochim Biophys Acta       Date:  1978-09-18

3.  Absence of reaction of a xenogenic anti-H-2 serum with mouse embryonal carcinoma cells.

Authors:  D Morello; G Gachelin; P Dubois; N Tanigaki; D Pressman; F Jacob
Journal:  Transplantation       Date:  1978-08       Impact factor: 4.939

4.  The presence of F9 antigen on the surface of mouse embryonic cells until day 8 of embryogenesis.

Authors:  M H Buc-Caron; H Condamine; F Jacob
Journal:  J Embryol Exp Morphol       Date:  1978-10

5.  Combined immunodeficiency disease associated with absence of cell-surface HLA-A and -B antigens.

Authors:  J L Touraine; H Betuel; G Souillet; M Jeune
Journal:  J Pediatr       Date:  1978-07       Impact factor: 4.406

6.  Differential expression of Ia molecules by human monocytes.

Authors:  T A Gonwa; J D Stobo
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

7.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

8.  Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon.

Authors:  I Heron; M Hokland; K Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Control of HLA-A,B,C synthesis and expression in interferon-treated cells.

Authors:  O R Burrone; C Milstein
Journal:  EMBO J       Date:  1982       Impact factor: 11.598

View more
  3 in total

Review 1.  TAP deficiency syndrome.

Authors:  S D Gadola; H T Moins-Teisserenc; J Trowsdale; W L Gross; V Cerundolo
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Diagnosis of genetic disease using recombinant DNA.

Authors:  D N Cooper; J Schmidtke
Journal:  Hum Genet       Date:  1986-05       Impact factor: 4.132

3.  HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1.

Authors:  H de la Salle; J Zimmer; D Fricker; C Angenieux; J P Cazenave; M Okubo; H Maeda; A Plebani; M M Tongio; A Dormoy; D Hanau
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.